Tous Actualités
Suivre
Abonner IsoTis OrthoBiologics

IsoTis OrthoBiologics

IsoTis Files Definitive Proxy Statement

Irvine, California (ots/PRNewswire)

- Special Stockholders Meeting to Approve Merger With Integra on
October 11, 2007
IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company,
today announced the filing of a definitive proxy statement with the
U.S. Securities and Exchange Commission ("SEC") in connection with
the IsoTis-Integra LifeSciences Holdings Corporation (NASDAQ: IART)
("Integra") combination. The proxy statement is available on the
investor portion of the company's corporate website, and was first
mailed to stockholders on or about September 5, 2007.
The Proxy Statement relates to a special meeting of stockholders
of IsoTis to be held on October 11, 2007 in Irvine, CA,, at which
IsoTis' stockholders will be asked to approve the acquisition of
IsoTis by Integra pursuant to an agreement and plan of merger dated
as of August 6, 2007. If the acquisition is consummated, stockholders
will be entitled to receive $7.25 in cash, without interest, for each
share of IsoTis common stock that they own.
IsoTis will also distribute to its stockholders a separate
document that highlights certain important components of the proxy
statement and translates these components into Dutch, French and
German. These highlights and translations will be mailed to
stockholders and are made available on the investor portion of the
company's corporate website.
In addition, in advance of the October 11, 2007 stockholder
meeting, IsoTis intends to hold information meetings for its European
stockholders on the following dates:
  • September 25, 2007, 6 p.m., local time, at Hôtel Alpha-Palmiers, located in Lausanne, Switzerland
  • September 26, 2007, 6 p.m., local time, at Hotel Baur au Lac, located in Zurich, Switzerland
  • September 27, 2007, 6 p.m., local time, at World Trade Center Schiphol Airport, located in Amsterdam, The Netherlands
The purpose of these meetings is to provide stockholders with an
opportunity to ask questions regarding the acquisition of IsoTis by
Integra. Stockholders will not be asked to vote on the transaction
during these information meetings. IsoTis stockholders will vote on
the transaction at the October 11, 2007 special meeting of
stockholders to be held in Irvine, California.
About IsoTis
IsoTis is an orthobiologics company that develops, manufactures
and markets proprietary products for the treatment of musculoskeletal
diseases and disorders. IsoTis' current orthobiologics products are
bone graft substitutes that promote the regeneration of bone and are
used to repair natural, trauma-related and surgically-created defects
common in orthopedic procedures, including spinal fusions. IsoTis'
current commercial business is highlighted by its Accell line of
products, which the company believes represents the next generation
in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have
reached a definitive agreement to create a global orthobiologics
leader. The combination would create a comprehensive orthobiologics
portfolio, one of the largest sales organizations focused on
orthobiologics in the US, and multiple cross-selling opportunities.
The transaction is subject to approval of IsoTis' stockholders, as
well as other closing conditions and approvals. Upon closing, IsoTis
will become a wholly-owned subsidiary of Integra and Integra will be
one of the largest companies in the world focused on advanced
technology in orthobiologics.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, IsoTis' proposed acquisition by
Integra. Words such as "strategy," "expects," "plans," "anticipates,"
"believes," "may," "will," "might," "could," "would," "continues,"
"estimates," "intends," "pursues," "projects," "goals," "targets" or
the negative or other variations thereof and other words of similar
meaning are intended to identify such forward-looking statements. One
can also identify them by the fact that they do not relate strictly
to historical or current facts. Such statements are based on the
current expectations and projections of the management of IsoTis
only. Undue reliance should not be placed on these statements
because, by their nature, they are subject to known and unknown risks
and can be affected by factors that are beyond the control of IsoTis.
Actual results could differ materially from current expectations and
projections. Any forward-looking statements are made pursuant to the
Private Securities Litigation Reform Act of 1995 and, as such, speak
only as of the date made. IsoTis undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Important Information for Investors and Stockholders
IsoTis has filed a definitive proxy statement and other relevant
materials with the SEC in connection with the proposed merger with
Integra. IsoTis urges IsoTis stockholders to read the proxy statement
and any other relevant documents filed by IsoTis with the SEC because
they will contain important information. Investors and stockholders
may obtain the proxy statement and other documents filed with the SEC
free of charge at the website maintained by the SEC at www.sec.gov.
Documents filed with the SEC by IsoTis are also available free of
charge on the investor relations portion of the IsoTis website at
www.IsoTis.com. The proxy statement was first mailed to stockholders
on or about September 5, 2007.
Participants in the Solicitation
IsoTis, and its directors and executive officers may be deemed to
be participants in the solicitation of proxies from IsoTis'
stockholders in connection with the proposed merger with Integra. The
names of IsoTis' directors and executive officers and a description
of their interests in IsoTis are set forth in IsoTis S.A.'s Annual
Report on Form 20-F, which was filed with the SEC on May 11, 2007.
Investors and stockholders can obtain more detailed information
regarding the direct and indirect interests of IsoTis' directors and
executive officers in the merger by reading the definitive proxy
statement.

Contact:

For information contact: Rob Morocco, CFO Hans Herklots, Director IR,
+1-949-855-7155 +1-949-855-7195 or +41-21-620-6011,
robert.morocco@isotis.com, hans.herklots@isotis.com

Plus de actualités: IsoTis OrthoBiologics
Plus de actualités: IsoTis OrthoBiologics
  • 20.08.2007 – 14:31

    IsoTis Receives FDA Clearance for Accell Family of Products

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it received a letter dated August 15, 2007 from the US Food and Drug Administration ("FDA"), clearing the Accell Family of Products for marketing in the US as Class II medical devices. The Accell Family of Products includes Accell 100, Accell Connexus and Accell Total Bone Matrix, as well as ...

  • 03.08.2007 – 16:19

    IsoTis to Release Second Quarter 2007 Results on August 7

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDQ: ISOT), a leading orthobiologics company, will release its 2007 second quarter results before opening of trading on Tuesday, August 7, 2007. To discuss these results, the Company will conduct a conference call at 4:00 p.m. (Eastern Time) / 1:00 p.m. (Pacific Time)/ 10:00 p.m. (Central European Time). Dial in details will be provided in the Q2 2007 release on ...